Immunochemotherapy for Metastatic Renal Cell Carcinoma

NCT00226798 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma Clear Cell

Interventions

DRUG: Capecitabine (Xeloda)

Sponsor

Rambam Health Care Campus

Collaborators

[object Object]